VITROS SARS CoV2 antigen assay – Procedural Steps: –
Stage 1: Nasopharyngeal swab specimen assortment:
1. Purchase a nasopharyngeal swab specimen by inserting the sterile swab into the nostril.
2. Push the sterile swab until resistance is met on the stage of the turbinate.
3. Rotate the sterile swab plenty of events in direction of the nasopharyngeal wall & go away throughout the place for
10 seconds to saturate the swab tip.
4. Take away the swab from the nostril fastidiously.
5. Place the swab specimen into the viral transport medium buffer tube and shut the tube tightly.
6. Transport the swab sample in VTM to the laboratory in a cold chain.
7. The sample may very well be saved in Room temperature (Beneath 30◦C) for as a lot as 24 hrs from the time of
sample assortment or at 2 – 8◦C for as a lot as 48 hrs from the time of sample assortment.
Diagnostics
1. The VITROS SARS CoV2 Antigen assay is a chemiluminescent immunoassay meant for the qualitative
detection of SARS-CoV-2 nucleocapsid antigens in nasopharyngeal (NP) specimens from individuals who
are suspected of COVID-19 inside one to five days of the onset of indicators, or mid-turbinate specimens
collected from asymptomatic individuals.
2. The assay must be carried out in VITROS 3600 Immunodiagnostics system or VITROS 5600 / VITROS XT 7600
Constructed-in system from Ortho.
Features
COVID-19, Nasopharyngeal swabs
SKU:G61RHA20
AVAILABILITY:In Stock with The Lowest Value throughout the Market
SHIPMENT:Related Day Cargo Orders Sooner than 14
H00SIZE:20 Exams/KitSPECIFICITY:98.90%
Type
Immunochromatography speedy verify
Description
Lateral motion immunochromatographic assay that adopted twin color system.
For the qualitative detection of SARS-CoV-2 antigen from nasopharyngeal swab specimen.
The verify incorporates colloid gold conjugate pad and a membrane strip pre-coated with antibodies specific to SARS-CoV-2 antigen on the verify traces (T).
A visible black band (antibody-antigen-antibody gold conjugate sophisticated) appears on the verify traces (T) If SARS-CoV-2 antigen is present throughout the specimen.
The administration line (C) reveals that verify is carried out appropriately.
Evaluated with panel specimen (n = 75) by PCR
Sensitivity: 90,2 %
Specificity: 100 %
Guidance for use of VITROS SARS CoV2 Antigen CLIA based Examine from Ortho Medical
Calibration Differ
Qualitative
Stage 2: Sample preparation for testing:
1. Sample preparation should be carried out in BSL-2 stage cabinet throughout the Laboratory.
2. Mix the swab specimen in VTM tube properly (vortex roughly 3-5 seconds).
3. Change 100 μL VITROS SARS-CoV-2 Antigen Extraction Buffer proper right into a labelled new sample tube.
4. Add 400 μL viral sample to the above tube (to deal with 1:4 ratio of extraction buffer: sample)
5. Mix properly (Cap/Plug the sample tube and vortex roughly 3-5 seconds).
Truenat™ COVID-19 |
|||
601430005 | Molbio Diagnostics Private Limited | 5T | EUR 60 |
Truenat™ COVID-19 |
|||
601430020 | Molbio Diagnostics Private Limited | 20T | EUR 240 |
Truenat™ COVID-19 |
|||
601430050 | Molbio Diagnostics Private Limited | 50T | EUR 600 |
COVID-19 Spike Antigen |
|||
30-2018 | Fitzgerald | 1 mg | EUR 400 |
Description: COVID-19 Spike recombinant antigen |
COVID-19 Spike Antigen |
|||
30-2019 | Fitzgerald | 1 mg | EUR 400 |
Description: COVID-19 Spike recombinant antigen |
COVID-19 Nucleocapsid protein |
|||
30-2005 | Fitzgerald | 1 mg | EUR 700 |
Description: COVID-19 Nucleocapsid protein recombinant antigen |
COVID-19 Nucleocapsid protein |
|||
30-2006 | Fitzgerald | 1 mg | EUR 700 |
Description: COVID-19 Nucleocapsid protein recombinant Antigen |
COVID-19 Nucleocapsid antigen |
|||
30-2020 | Fitzgerald | 1 mg | EUR 400 |
Description: COVID-19 Nucleocapsid recombinant protein |
COVID-19 Nucleocapsid antigen |
|||
30-2021 | Fitzgerald | 1 mg | EUR 400 |
Description: COVID-19 Nucleocapsid recombinant protein |
COVID-19 Nucleoprotein antibody |
|||
10-2890 | Fitzgerald | 1 mg | EUR 420 |
Description: Purified COVID-19 Nucleoprotein Antibody |
COVID-19 Nucleoprotein antibody |
|||
10-2891 | Fitzgerald | 1 mg | EUR 420 |
Description: Purified COVID-19 Nucleoprotein Antibody |
COVID-19 Nucleoprotein antibody |
|||
10-2894 | Fitzgerald | 1 mg | EUR 420 |
Description: Purified COVID-19 Nucleoprotein Antibody |
STAT-NAT COVID-19 B |
|||
BSV-qPCR-12 | BioServUK | 24 tests | Ask for price |
Description: STAT-NAT COVID-19 B |
STAT-NAT COVID-19 HK |
|||
BSV-qPCR-13 | BioServUK | 24 tests | Ask for price |
Description: STAT-NAT COVID-19 HK |
COVID-19 IgG & IgM antibody |
|||
GEN-50001-50tests | Ring Bio | 50 tests | EUR 388.8 |
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus. |
STAT-NAT COVID-19 MULTI |
|||
BSV-qPCR-11 | BioServUK | 96 tests | Ask for price |
Description: STAT-NAT COVID-19 MULTI |
Coronavirus (COVID-19) CE IVD |
|||
PRD-Z-Path-COVID-19-CE | BioServUK | 96 tests | Ask for price |
Description: Coronavirus (COVID-19) CE IVD |
COVID-19 Antigen Rapid Test |
|||
ICOV-802H | Hangzhou AllTest Biotech | 25 Tests | EUR 12.5 |
COVID-19 Antigen Detection Kit |
|||
BSV-G61RHA20 | BioServUK | 20 tests | Ask for price |
Description: COVID-19 Antigen Detection Kit |
BioSURE COVID-19 IgG Antibody Self-Test |
|||
BSV-C19 | BioServUK | 1 Test | Ask for price |
Description: BioSURE COVID-19 IgG Antibody Self-Test |
COVID-19 nucleoprotein ELISA Kit |
|||
EKF60838-48T | Biomatik Corporation | 48T | EUR 400.4 |
COVID-19 nucleoprotein ELISA Kit |
|||
EKF60838-5x96T | Biomatik Corporation | 5x96T | EUR 2717 |
COVID-19 nucleoprotein ELISA Kit |
|||
EKF60838-96T | Biomatik Corporation | 96T | EUR 572 |
COVID-19 Envelope Protein Antibody |
|||
E38PA9967 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
COVID-19 Spike glycoprotein Antibody |
|||
E38PA9966 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
COVID-19 Nucleocapsid Protein Antibody |
|||
E38PA9965 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
COVID-19 Nucleocapsid recombinant antigen |
|||
00221-V-100ugvial | Virogen | 100 ug/vial | EUR 150 |
Description: COVID-19 Nucleocapsid recombinant antigen |
COVID-19 Nucleocapsid recombinant antigen |
|||
00221-V | Virogen | 1 MG | EUR 850 |
Nadal COVID-19 IgG/IgM Test |
|||
BSV-243001N-10 | BioServUK | 10 tests | Ask for price |
Description: Nadal COVID-19 IgG/IgM Test |
COVID-19 (SARS-CoV-2) IgG |
|||
DECOV1901 | Demeditec Diagnostics | 96 | EUR 232 |
COVID-19 (SARS-CoV-2) IgA |
|||
DECOV1902 | Demeditec Diagnostics | 96 | EUR 232 |
GA COVID-19 Rapid Antigen Test |
|||
BSV-3980 | BioServUK | 20 tests | Ask for price |
Description: GA COVID-19 Rapid Antigen Test |
SARS-CoV-2 (COVID-19) Spike Antibody (biotin) |
|||
3525-biotin-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike Antibody (biotin) |
|||
3525-biotin-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |